(E)-benzyl 3-aminobut-2-enoate | 43107-11-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-benzyl 3-aminobut-2-enoate
• 英文别名: benzyl 3-amino-2-butenoate；(Z)-Benzyl 3-aminobut-2-enoate；benzyl (E)-3-aminobut-2-enoate
• CAS: 43107-11-5
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: LPYNWRPARGBJOL-VQHVLOKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-benzyl 3-aminobut-2-enoate 在 硝酸 、 溶剂黄146 作用下， 以 水 、 异丙醇 为溶剂， 反应 36.0h， 生成 3-benzyl 5-ethyl 6-(chloromethyl)-4-(2,4-dichlorophenyl)-2-methylpyridine-3,5-dicarboxylate
  参考文献：
  名称：

  Optimization of Activity, Selectivity, and Liability Profiles in 5-Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate (Sa)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778)

  摘要：

  Optimization of a 5-oxopyrrolopyridine series based upon structure activity relationships (SARs) developed from our previous efforts on a number of related bicyclic series yielded compound 2s (BMS-767778) with an overall activity, selectivity, efficacy, PK, and developability profile suitable for progression into the clinic. SAR in the series and characterization of 2s are described.

  DOI：

  10.1021/jm4008906
• 作为产物：
  描述：

  乙酰丙酮苄酯 在 ammonium acetate 作用下， 以 甲醇 为溶剂， 反应 72.0h， 以90%的产率得到(E)-benzyl 3-aminobut-2-enoate
  参考文献：
  名称：

  Optimization of Activity, Selectivity, and Liability Profiles in 5-Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate (Sa)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778)

  摘要：

  Optimization of a 5-oxopyrrolopyridine series based upon structure activity relationships (SARs) developed from our previous efforts on a number of related bicyclic series yielded compound 2s (BMS-767778) with an overall activity, selectivity, efficacy, PK, and developability profile suitable for progression into the clinic. SAR in the series and characterization of 2s are described.

  DOI：

  10.1021/jm4008906

文献信息

• 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives
  作者：Kelvin Cooper、M. Jonathan Fray、M. John Parry、Kenneth Richardson、John Steele

  DOI：10.1021/jm00095a005

  日期：1992.8

  A novel class of 2-(4-heterocyclylphenyl)-1,4-dihydropyridines (2-38) possessing antagonist activity against platelet activating factor (PAF) was prepared by the Hantzsch synthesis from a variety of ethyl 4'-heterocyclic-substituted benzoylacetates, aryl or heteroaryl aldehydes, and substituted 3-aminocrotonamides or 3-aminocrotonate esters. Structure-activity relationships were evaluated where PAF

  利用多种4'-杂环取代的苯甲酰乙酸乙酯通过Hantzsch合成方法制备了一类对血小板活化因子（PAF）具有拮抗活性的2-（4-杂环基苯基）-1,4-二氢吡啶（2-38） ，芳基或杂芳基醛，以及取代的3-氨基巴豆酰胺或3-氨基巴豆酸酯。评估了结构活性关系，其中通过测定抑制PAF诱导的兔洗涤血小板聚集所需的化合物浓度（IC50）在体外测量PAF拮抗剂活性，并通过确定保护小鼠的口服剂量（ED50）在体内测量PAF拮抗剂活性致命注射PAF。发现二氢吡啶2位上的取代基对于体外和体内活性均很重要，而4位和5位的结构变化具有更大的灵活性。最有效的化合物是4-（2-氯苯基）-1,4-二氢-3-（乙氧羰基）-6-甲基-2- [4-（2-甲基咪唑并[4,5-c]吡啶-1-基）苯基] -5- [N-（2-吡啶基）氨基甲酰基]吡啶（17，UK-74,505），IC50 = 4.3 nM，ED50 = 0.26 mg
• [EN] BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME<br/>[FR] COMPOSÉS ÉMISSIFS CYCLIQUES CONTENANT DU BORE ET FILM DE COLORISATION CONTENANT CEUX-CI
  申请人：NITTO DENKO CORP

  公开号：WO2020210761A1

  公开（公告）日：2020-10-15

  The present disclosure relates to novel photoluminescent complexes comprising a BODIPY moiety covalently bonded to a blue light absorbing moiety, a color conversion film comprising the photoluminescent complex, and a back-light unit using the same.

  本公开涉及新型的光致发光配合物，该配合物包括与蓝色光吸收基团共价键结合的BODIPY部分，包含该光致发光配合物的色转换膜，以及使用该配合物的背光单元。
• Design and Synthesis of Novel α_1a Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia
  作者：Dhanapalan Nagarathnam、John M. Wetzel、Shou Wu Miao、Mohammad R. Marzabadi、George Chiu、Wai C. Wong、Xingfang Hong、James Fang、Carlos Forray、Theresa A. Branchek、William E. Heydorn、Raymond S. L. Chang、Theodore Broten、Terry W. Schorn、Charles Gluchowski

  DOI：10.1021/jm980506g

  日期：1998.12.1

  We report the synthesis and evaluation of novel alpha(1a) adrenoceptor subtype-selective antagonists. Systematic modification of the lipophilic 4,4-diphenylpiperidinyl moiety of the dihydropyridine derivatives 1 and 2 provided several highly selective and potent alpha(1a), antagonists. From this series, we identified the 4-(methoxycarbonyl)-4-phenylpiperidine analogue SNAP 5540 (-) [(-)-63] for further characterization. When examined in an isolated human prostate tissue assay, this compound was found to have a K-i of 2.8 nM, in agreement with the cloned human receptor binding data (K-i = 2.42 nM). Further evaluation of the compound in isolated dog prostate tissue showed a K-i of 3.6 nM and confirmed it to be a potent antagonist (K-b = 1.6 nM). In vivo, this compound effectively blocked the phenylephrine-stimulated increase in intraurethral pressure (IUP) in mongrel dogs, at doses which did not significantly affect the arterial pressure (diastolic blood pressure, DBP), with a DBP K-b/IUP K-b ratio of 16. In addition, (-)-63 also showed greater than 40 000-fold selectivity over the rat L-type calcium channel and 200-fold selectivity over several G protein-coupled receptors, including histamine and serotonin subtypes. These findings prove that alpha(1a) adrenoceptor-subtype selective antagonists such as (-)-63 may be developed as uroselective agents for an improved treatment of BPH over nonselective alpha(1) antagonists such as prazosin and terazosin, with fewer side effects.
• 6-Phenyl-1,4-dihydropyridine Derivatives as Potent and Selective A₃ Adenosine Receptor Antagonists
  作者：Ji-long Jiang、A. Michiel van Rhee、Neli Melman、Xiao-duo Ji、Kenneth A. Jacobson

  DOI：10.1021/jm960457c

  日期：1996.1.1

  An approach to designing dihydropyridines that bind to adenosine receptors without binding to L-type calcium channels has been described. 1,4-Dihydropyridine derivatives substituted with beta-styryl or phenylethynyl groups at the 4-position and aryl groups at the 6-position were synthesized and found to be selective for human A(3) receptors. Combinations of methyl, ethyl, and benzyl esters were included at the 3- and 5-positions. Affinity was determined in radioligand binding assays at rat brain A(1) and A(2A) receptors using [H-3]-(R)-PIA [[H-3]-(R)-N-6-(phenylisopropyl)adenosine] and [H-3]CGS 21680 [[H-3]-2-[[4-(2-carboxymethyl)phenyl]ethylamino]-5'-(N-ethyl carbamoyl)adenosine], respectively. Affinity was determined at cloned human and rat A(3) receptors using [I-125]AB-MECA [N-6-(4-amino-3-iodobenzyl)-5'-(N-methycarbonyl)adenosine]. Structure-activity analysis indicated that substitution of the phenyl ring of the beta-styryl group but not of the 6-phenyl substituent was tolerated in A(3) receptor selective agents. Replacement of the 6-phenyl ring with a 3-thienyl or 3-furyl group reduced the affinity at A(3) receptors by 4- and g-fold, respectively. A 5-benzyl ester 4-trans-beta-styryl derivative, 26, with a K-i value of 58.3 nM at A(3) receptors, was >1700-fold selective vs either A(1) receptors or A(2A) receptors. Shifting the benzyl ester to the 3-position lowered the affinity at A(3) receptors 3-fold. A 5-benzyl, 3-ethyl ester 4-phenylethynyl derivative, 28, displayed a K-i value of 31.4 nM at A(3) receptors and 1300-fold selectivity vs A(1) receptors. The isomeric 3-benzyl, 5-ethyl diester was >600-fold selective for A(3) receptors. Oxidation of 28 to the corresponding pyridine derivative reduced affinity at A(3) receptors by 88-fold and slightly increased affinity at A(1) receptors.
• CHYLINSKA J. B., POL. J. CHEM., 1979, 53, NO 3, 725-730
  作者：CHYLINSKA J. B.

  DOI：——

  日期：——